Skip to content
lifestyle.tasteterminal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Indivior Pharmaceuticals Inc.
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
May 22, 2026
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
May 21, 2026
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
May 20, 2026
Indivior Announces $175 Million Accelerated Share Repurchase
May 15, 2026
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
April 16, 2026
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
April 9, 2026
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
March 31, 2026
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
March 17, 2026
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
March 12, 2026
Indivior Announces Proposed Convertible Senior Notes Offering
March 12, 2026
1
2
Next Page
→